CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 30 enrolled
Drug / intervention
BCG TICE Vaccinebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04884308
NCT04884308Phase 2Completed
CompareCT.gov

Effects of BCG Vaccine on the Immune System of Individuals With Cystic Fibrosis, Non-Cystic Fibrosis Bronchiectasis, and Healthy Volunteers

Johns Hopkins University·interventional·Posted May 12, 2021·Updated Feb 10, 2025

In Brief

A Phase 2 clinical trial evaluating BCG TICE Vaccine for Cystic Fibrosis and 2 related conditions. Completed, enrolled 30 participants across 1 site.

Detailed Summary

This is pilot study of the immunologic effects of intradermal Bacille Calmette-Guerin (BCG) vaccination of adults with cystic fibrosis (CF), non-CF bronchiectasis (NCFB), and healthy volunteers.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCystic Fibrosis, Bronchiectasis Adult, Non-Tuberculous Mycobacteria
CountriesUnited States
CollaboratorsCystic Fibrosis Foundation

Timeline

Phase 2CompletedFinished
20222023202420252026
First PostedMay 12, 2021
Enrollment StartApr 28, 2021
Primary CompletionDec 30, 2023
TodayJul 2, 2026
Enrollment to primary: 2.7 yearsPosted 5.1 years ago

Interventions

BCG TICE Vaccinebiological

Intradermal vaccination with BCG TICE